Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

i>Ampyra, the first drug approved by the FDA to improve walking in MS patients. The qualitative portion also examines the current reimbursement climate for multiple sclerosis drugs as well as the response from managed care organizations to Gilenya and other new MS drugs in development.

About Event Pulse

Event Pulse is a syndicated report series that evaluates the impact of market events on physician treatment practices. These report series provide information on how changes such as new products, data, or guidelines fit into the treatment algorithm, impact current therapies and change market dynamics.

About ITG Majestic Market Research

ITG Majestic Market Research is the primary market research offering of ITG, an independent agency research brokerage firm founded in 1987. Since 2002, ITG has revolutionized the research business with its differentiated research platform based upon leveraging large amounts of statistically relevant, real-time data. While traditional research is frequently based on publicly available data, anecdotal information and channel checks of limited sample sizes, the company leverages its exclusive relationships with industry data providers, proprietary Web harvesting technology and rigorous primary research capabilities to generate fresh insights from superior analysis of a vast array of data.

ITG is a specialist in delivering the highest quality, healthcare market intelligence quickly -- combining survey results with proprietary empirical data to deliver innovative syndicated and custom reporting. Our cutting edge, market research capabilities enable us to provide clients with the intelligence and clarity they need to make informed business
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, the ... Champions Tour, is rounding out its debut year of ... Scottsdale, AZ. This marks the ... Champions Tour that the brand has activated on-site with ... educate golf fans on the importance of joint health.  ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... 2012 Sorbent Therapeutics, Inc. a biopharmaceutical company developing ... from its Phase 2a clinical study of CLP1001.  In ... kidney disease, CLP1001 demonstrated improvement in heart failure symptoms ... the randomized, double-blind Phase 2a study were presented in ...
...  Eli Lilly and Company (NYSE: LLY ) ... 1 (GLP-1) analog being studied as a once-weekly treatment ... non-inferiority for mean 24-hour systolic blood pressure (SBP, or ... results came from a Phase II study that compared ...
Cached Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 2Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 3Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting 4
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 REV'D Provision ... are now available through a unique service called, ... designed to empower the everyday athlete. The Feed has ... athletes and created a system to pass that information ... see REV’D® is now available on The Feed!” says ...
(Date:10/30/2014)... Victory Healthcare, a privately owned ... quarter infection rates and patient satisfaction scores. The ... only two percent or less, and the medical ... percent. , “We are delighted with our strong ... scores,” said Robert Helms, chairman and CEO of ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... (HealthDay News) -- Many U.S. colleges have indoor ... tanning increases the risk for skin cancer, researchers ... particularly white women, so colleges should adopt tanning-free ... said. "Public health efforts are needed to ... the harms that indoor tanning poses to young ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... risk of hypertension, hardening of arteries , , FRIDAY, May 15 ... harbor could be a cause of high blood pressure, animal ... likely to develop not only high blood pressure but also ... report in the May 15 issue of PLoS Pathogens ...
... Boston Scientific Corporation (NYSE: BSX ) ... news announcements at the annual EuroPCR Scientific Program, which ... are pleased to be announcing additional analyses from the ... outcomes, as well as insights on the design and ...
... ATLANTA, May 15 Paul Capital Healthcare today announced ... a panel on non-traditional forms of financing at the ... with how to evaluate non-dilutive financing options that can ... development, the panel, "Non-dilutive and Other Non-traditional Forms of ...
... establish Group B Strep colonization of pregnant women and ... newbornsGBS PNA FISH shown to detect up to 42% ... and VEDBAEK, Denmark, May 15 AdvanDx today announced ... for detection of Streptococcus agalactiae , aka Group ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and ... ... (PRWEB) May 15, 2009 -- Kinovate Life Sciences, Inc, the ... announcing the successful development of its next generation high loading ...
Cached Medicine News:Health News:Viral Infection Might Trigger High Blood Pressure 2Health News:Viral Infection Might Trigger High Blood Pressure 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 2Health News:Boston Scientific Announces Schedule for EuroPCR 2009 3Health News:Boston Scientific Announces Schedule for EuroPCR 2009 4Health News:Boston Scientific Announces Schedule for EuroPCR 2009 5Health News:Boston Scientific Announces Schedule for EuroPCR 2009 6Health News:Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 3Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 2Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 3Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 4
... Excellent performance, small footprint, simple intuitive programming ... Primus 25 the ideal personal cycler in ... flexiblock design and the self-adjusting heated lid ... 13x 0.5ml vessels or a microplate of ...
... 96 temperature cyclers, the gradient block can be ... up to 14 or 22 across the 40- ... of up to 2C between adjacent wells in ... to 12 different annealing temperatures in a single ...
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... analysis software, Beacon Designer oligo software, ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
Medicine Products: